- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Rationale:
- Decision makers have concluded that a new technology appraisal is not necessary for this licence extension. The guidance in development for Efgartigimod for treating generalised myasthenia gravis [ID4003] will consider the sub-cut formulation, but there will not be a specific recommendation on it, as per standard NICE practice. Please see Section 6.2.1 of the Topic Selection Manual states that: Medicines that meet the eligibility criteria will be selected, except when there is a clear rationale not to do so. For example, when: changes to the dose, formulation or administration will not significantly affect the clinical and cost effectiveness of the medicine.
- ID number:
- 11835
Project Team
- Project lead
- Abigail Stephens
Email enquiries
If you have any queries please email topic.selection@nice.org.uk
For further information on how we select topics for development, please see our page about topic prioritisation